Tempus AI, Inc.
TEM
Positions held
Your positionsTEM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Tempus AI, Inc. operates in the rapidly growing health information services sector, which is increasingly vital for personalized medicine and data-driven healthcare solutions.
- Revenue increased by 10% compared to the prior quarter, reaching $382 million.
- Gross margin improved to 64.4%, up from 63.8% in the previous quarter.
- The company has a high debt-to-equity ratio of 324.58, indicating significant financial leverage and potential risk.
- Net income for the most recent quarter was a loss of $125.919 million.
- Operating margin remains negative at -19.8%, reflecting ongoing challenges in profitability.
Fundamentals
| Market cap | $12.50B | Enterprise value | $13.13B | Trailing P/E | — | Forward P/E | -8,563.66 |
| PEG | — | Price / book | 28.04 | Beta | 3.54 | Dividend yield | 0.00% |
| Revenue growth | 21.6% | Earnings growth | — | Gross margin | 64.0% | Operating margin | -20.1% |
| Profit margin | -17.8% | ROE | -67.4% | ROA | -8.5% | Debt / equity | 3.25 |
| Current ratio | 3.30 | Free cash flow | -$93.49M | Analyst recommendation | buy | Mean target | $71.44 |
| 52w high | $101.56 | 52w low | $40.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $382M | $348M | $367M | $334M | $315M | — |
| Op margin | -19.8% | -24.3% | -16.7% | -18.3% | -19.6% | — |
| Net income | $5.6M | -$126M | -$54.2M | -$80.0M | -$42.8M | — |
| Gross margin | 64.4% | 63.8% | 64.7% | 62.8% | 62.0% | — |
| Gross profit | $246M | $222M | $238M | $210M | $195M | — |
| Operating income | -$75.9M | -$84.7M | -$61.4M | -$61.0M | -$61.8M | — |
- Revenue +10% vs prior quarter ($382M vs $348M).
- Gross margin 64.4% (was 63.8% prior quarter).
- Operating margin expanded to -19.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $693M | $532M | $321M | — |
| Op margin | -19.9% | -99.7% | -36.9% | -82.8% | — |
| Net income | -$245M | -$706M | -$214M | -$290M | — |
| Gross margin | 62.7% | 55.0% | 53.8% | 40.6% | — |
| Gross profit | $798M | $381M | $286M | $130M | — |
| Operating income | -$253M | -$691M | -$196M | -$265M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Tempus Expands Moderna, Merck Collaboration for Individualized Cancer Therapy
2026-10-07 · Tempus Announces Multi-Year Collaboration with Moderna and Merck
2026-10-07 · Dow Jones Futures Fall, Yields Jump After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys
2026-10-06 · Fortune Unveils the "Fortune Future 120" 2026 List
2026-10-06 · Tempus AI (TEM) Shares Just Moved, So What Is Going On?
2026-10-05 · Here's How Tempus AI is Capitalizing on AI-ECG Market Growth
2026-10-01 · AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
2026-10-01 · Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
2026-09-30 · Cathie Wood Sold $110 Million of AMD and Bought Nvidia Instead
2026-09-29 · Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
2026-09-29 · Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
2026-09-29 · Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
Price (daily)
Full chart · RSI · MACD · patterns